CD30-targeted cell treatment for hard-to-treat blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial studies an experimental treatment that targets a marker called CD30 on cancer cells. It is for adults with certain relapsed or refractory CD30-positive blood cancers to see how well the treatment works and what side effects it causes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed blood cancer diagnosis (Hodgkin lymphoma, non-Hodgkin lymphoma, AML, ALL, or another hard-to-treat blood cancer).
- Your tumor must be CD30-positive based on recent lab/pathology or flow test results.
- Your cancer must be in an active stage that can be measured (for lymphomas) or still present after prior treatment (for leukemias).
- You must be at least 18, and able to live independently enough for a clinic activity score of at least 50%.
- Your body needs to be well enough to handle treatment: adequate kidney, liver, oxygen levels, and heart function based on lab tests and scans.
- You must have recovered from side effects of prior treatments and be far enough from recent chemo/immunotherapy/other therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy for CD30-positive lymphomas. The cells are made from donated blood and are designed to find and attack your cancer.
This trial tests a new treatment called CD30 CAR-T, which uses your own immune cells to attack lymphoma cells that have the CD30 protein. It is for people whose lymphoma has come back or not responded to at least 2 prior treatments.
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
This trial tests a new type of immunotherapy called CD30 CAR-T cells for people with CD30-positive lymphoma that has come back or hasn't responded to other treatments. The treatment uses your own immune cells that are specially trained to find and kill lymphoma cells carrying the CD30 marker.
This trial tests a new treatment made from your own immune cells, which are modified to find and attack CD30-positive lymphoma cells. It is for people with Hodgkin or non-Hodgkin lymphoma that has come back or not responded to other treatments.
This trial tests a new treatment using your own immune cells (T-cells) that are specially designed to attack a protein called CD30 found on Hodgkin lymphoma cells. It's given after a stem cell transplant to try to prevent the cancer from coming back in people with high-risk disease.
Hear when a new Hodgkin Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.